COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07TJM
|
|||
| Drug Name |
PMID30784880-compound-6-5
|
|||
| Synonyms |
PMID30784880-C-6-5
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Severe acute respiratory syndrome (SARS) | Preclinical | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] |
| Pyrithiobac derivatives 6-5 exhibits a promising inhibitory activity against SARS-CoV Mpro with IC50 of 4.471 microM. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives. Eur J Med Chem. 2019 Apr 1;167:472-484. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.